Mir-34: A new weapon against cancer?

Molecular Therapy Nucleic Acids

Volumn 3, Issue , 2014, Pages e195-

  Misso, Gabriella ^a   Di Martino, Maria Teresa ^b   De Rosa, Giuseppe ^c   Farooqi, Ammad Ahmad ^d   Lombardi, Angela ^a   Campani, Virginia ^c   Zarone, Mayra Rachele ^a   Gullà, Annamaria ^b   Tagliaferri, Pierosandro ^b   Tassone, Pierfrancesco ^b,e   Caraglia, Michele ^b,e  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d Laboratory for Translational Oncology and Personalized Medicine   (Pakistan)

^e Temple University   (United States)

Author keywords

Apoptosis; Cancer; Cell cycle; Delivery; DNA damage; MicroRNA; miR 34a; Multiple myeloma; Nanotechnology; p53

Indexed keywords

ANDROGEN RECEPTOR; CISPLATIN; FLAVONE; FLUOROURACIL; HISTONE DEACETYLASE 1; INOSINATE DEHYDROGENASE; MACROPHAGE DERIVED CHEMOKINE; MICRORNA 34A; MUSASHI1 PROTEIN; NANOCARRIER; NANOPARTICLE; NATURAL KILLER CELL RECEPTOR NKG2D; NOTCH RECEPTOR; NUCLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLATELET DERIVED GROWTH FACTOR RECEPTOR; POTASSIUM CHANNEL HERG; PROTEIN BCL 2; PROTEIN KINASE INHIBITOR; PROTEIN MDMX; PROTEIN TYROSINE KINASE; PROTEINASE ACTIVATED RECEPTOR 2; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR 2; SIRTUIN 1; STEM CELL FACTOR RECEPTOR; SURVIVIN; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR SNAIL; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER STEM CELL; CELL CYCLE; CELL DIFFERENTIATION; CELL VIABILITY; CHEMICAL MODIFICATION; COLORECTAL CANCER; DNA DAMAGE; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; MOLECULARLY TARGETED THERAPY; NANOTECHNOLOGY; NON SMALL CELL LUNG CANCER; NONHUMAN; NUTRIGENOMICS; ONCOGENE C MYC; ONCOGENE SRC; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA TRANSLATION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT;

EID: 84925251992     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2014.47     Document Type: Review

References (149)

1. Calin, GA, Dumitru, CD, Shimizu, M, Bichi, R, Zupo, S, Noch, E et al. (2002). Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 15524-15529.
2. Volinia, S, Calin, GA, Liu, CG, Ambs, S, Cimmino, A, Petrocca, F et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261.
3. Calin, GA and Croce, CM (2006). MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866.
4. Croce, CM (2009). Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714.
5. Lu, J, Getz, G, Miska, EA, Alvarez-Saavedra, E, Lamb, J, Peck, D et al. (2005). MicroRNA expression profiles classify human cancers. Nature 435: 834-838.
6. Garzon, R, Marcucci, G and Croce, CM (2010). Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9: 775-789.
7. Ling, H, Fabbri, M and Calin, GA (2013). MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 12: 847-865.
8. Lionetti, M, Musto, P, Di Martino, MT, Fabris, S, Agnelli, L, Todoerti, K et al. (2013). Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin Cancer Res 19: 3130-3142.
9. Negrini, M, Cutrona, G, Bassi, C, Fabris, S, Zagatti, B, Colombo, M et al. (2014). microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters. Clin Cancer Res 20: 4141-4153.
10. Esquela-Kerscher, A and Slack, FJ (2006). Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
11. Dimopoulos, K, Gimsing, P and Grønbæk, K (2013). Aberrant microRNA expression in multiple myeloma. Eur J Haematol 91: 95-105.
12. Tagliaferri, P, Rossi, M, Di Martino, MT, Amodio, N, Leone, E, Gulla, A et al. (2012). Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets 12: 838-846.
13. Amodio, N, Di Martino, MT, Neri, A, Tagliaferri, P and Tassone, P (2013). Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. Expert Opin Biol Ther 13 (suppl. 1): S125-S137.
14. Rossi, M, Amodio, N, Di Martino, MT, Caracciolo, D, Tagliaferri, P and Tassone, P (2013). From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario. Curr Drug Targets 14: 1144-1149.
15. Rossi, M, Amodio, N, Di Martino, MT, Tagliaferri, P, Tassone, P and Cho, WC (2014). MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches. Curr Pharm Biotechnol 15: 459-467.
16. Tutar, L, Tutar, E and Tutar, Y (2014). MicroRNAs and Cancer; an Overview. Curr Pharm Biotechnol 15: 430-437.
17. Rolfo, C, Fanale, D, Hong, DS, Tsimberidou, AM, Piha-Paul, SA, Pauwels, P et al. (2014). Impact of MicroRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer. Curr Pharm Biotechnol 15: 475-485.
18. Thorsen, SB, Obad, S, Jensen, NF, Stenvang, J and Kauppinen, S (2012). The therapeutic potential of microRNAs in cancer. Cancer J 18: 275-284.
19. Bader, AG (2012). miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet 3: 120.
20. Bovell, LC, Putcha, BD, Samuel, T and Manne, U (2013). Clinical implications of microRNAs in cancer. Biotech Histochem 88: 388-396.
21. Amodio, N, Leotta, M, Bellizzi, D, Di Martino, MT, D'Aquila, P, Lionetti, M et al. (2012). DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget 3: 1246-1258.
22. Amodio, N, Di Martino, MT, Foresta, U, Leone, E, Lionetti, M, Leotta, M et al. (2012). miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis 3: e436.
23. Rossi, M, Pitari, MR, Amodio, N, Di Martino, MT, Conforti, F, Leone, E et al. (2013). miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol 228: 1506-1515.
24. Leone, E, Morelli, E, Di Martino, MT, Amodio, N, Foresta, U, Gullà, A et al. (2013). Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res 19: 2096-2106.
25. Di Martino, MT, Gullà, A, Cantafio, ME, Lionetti, M, Leone, E, Amodio, N et al. (2013). In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget 4: 242-255.
26. Amodio, N, Bellizzi, D, Leotta, M, Raimondi, L, Biamonte, L, D'Aquila, P et al. (2013). miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle 12: 3650-3662.
27. Leotta, M, Biamonte, L, Raimondi, L, Ronchetti, D, Martino, MT, Botta, C et al. (2014). A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro. J Cell Physiol 229: 2106-2116.
28. Raimondi, L, Amodio, N, Di Martino, MT, Altomare, E, Leotta, M, Caracciolo, D et al. (2014). Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget 5: 3039-3054.
29. Suzuki, H, Maruyama, R, Yamamoto, E and Kai, M (2012). DNA methylation and microRNA dysregulation in cancer. Mol Oncol 6: 567-578.
30. Hermeking, H (2010). The miR-34 family in cancer and apoptosis. Cell Death Differ 17: 193-199.
31. Di Martino, MT, Campani, V, Misso, G, Gallo Cantafio, ME, Gullà, A, Foresta, U et al. (2014). In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS ONE 9: e90005.
32. Di Martino, MT, Leone, E, Amodio, N, Foresta, U, Lionetti, M, Pitari, MR et al. (2012). Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 18: 6260-6270.
33. Iliou, MS, da Silva-Diz, V, Carmona, FJ, Ramalho-Carvalho, J, Heyn, H, Villanueva, A et al. (2014). Impaired DICER1 function promotes stemness and metastasis in colon cancer. Oncogene 33: 4003-4015.
34. Liu, C, Kelnar, K, Liu, B, Chen, X, Calhoun-Davis, T, Li, H et al. (2011). The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17: 211-215.
35. Nalls, D, Tang, SN, Rodova, M, Srivastava, RK and Shankar, S (2011). Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS ONE 6: e24099.
36. Stankevicins, L, Almeida da Silva, AP, Ventura Dos Passos, F, Dos Santos Ferreira, E, Menks Ribeiro, MC, G David, M et al. (2013). MiR-34a is up-regulated in response to low dose, low energy X-ray induced DNA damage in breast cells. Radiat Oncol 8: 231.
37. Guessous, F, Zhang, Y, Kofman, A, Catania, A, Li, Y, Schiff, D et al. (2010). microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle 9: 1031-1036.
38. Li, Z, Branham, WS, Dial, SL, Wang, Y, Guo, L, Shi, L et al. (2010). Genomic analysis of microRNA time-course expression in liver of mice treated with genotoxic carcinogen N-ethyl-N-nitrosourea. BMC Genomics 11: 609.
39. Yamakuchi, M and Lowenstein, CJ (2009). MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle 8: 712-715.
40. Basak, SK, Veena, MS, Oh, S, Lai, C, Vangala, S, Elashoff, D et al. (2013). The CD44(high) tumorigenic subsets in lung cancer biospecimens are enriched for low miR-34a expression. PLoS ONE 8: e73195.
41. Kofman, AV, Kim, J, Park, SY, Dupart, E, Letson, C, Bao, Y et al. (2013). microRNA-34a promotes DNA damage and mitotic catastrophe. Cell Cycle 12: 3500-3511.
42. De Antonellis, P, Carotenuto, M, Vandenbussche, J, De Vita, G, Ferrucci, V, Medaglia, C et al. (2014). Early Targets of miR-34a in Neuroblastoma. Mol Cell Proteomics 13: 2114-2131.
43. Rothe, K, Lin, H, Lin, KB, Leung, A, Wang, HM, Malekesmaeili, M et al. (2014). The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem/progenitor cells. Blood 123: 3622-3634.
44. Li, Y, Guessous, F, Zhang, Y, Dipierro, C, Kefas, B, Johnson, E et al. (2009). MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 69: 7569-7576.
45. Pang, RT, Leung, CO, Ye, TM, Liu, W, Chiu, PC, Lam, KK et al. (2010). MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis 31: 1037-1044.
46. de Antonellis, P, Medaglia, C, Cusanelli, E, Andolfo, I, Liguori, L, De Vita, G et al . (2011). MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumorpropagating cells and supports neural differentiation in medulloblastoma. PLoS ONE 6: e24584.
47. Bu, P, Chen, KY, Chen, JH, Wang, L, Walters, J, Shin, YJ et al. (2013). A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells. Cell Stem Cell 12: 602-615.
48. Winton, DJ (2013). miR-34a sets the "sweet spot" for notch in colorectal cancer stem cells. Cell Stem Cell 12: 499-501.
49. Yamamura, S, Saini, S, Majid, S, Hirata, H, Ueno, K, Deng, G et al. (2012). MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS ONE 7: e29722.
50. Yan, K, Gao, J, Yang, T, Ma, Q, Qiu, X, Fan, Q et al. (2012). MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS ONE 7: e33778.
51. Li, N, Fu, H, Tie, Y, Hu, Z, Kong, W, Wu, Y et al. (2009). miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 275: 44-53.
52. Tanaka, N, Toyooka, S, Soh, J, Tsukuda, K, Shien, K, Furukawa, M et al. (2013). Downregulation of microRNA-34 induces cell proliferation and invasion of human mesothelial cells. Oncol Rep 29: 2169-2174.
53. Zhang, Y, Schiff, D, Park, D and Abounader, R (2014). MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET. PLoS ONE 9: e91546.
54. Menges, CW, Kadariya, Y, Altomare, D, Talarchek, J, Neumann-Domer, E, Wu, Y et al. (2014). Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. Cancer Res 74 : 1261-1271.
55. Siemens, H, Jackstadt, R, Kaller, M and Hermeking, H (2013). Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget 4: 1399-1415.
56. Zhao, G, Guo, J, Li, D, Jia, C, Yin, W, Sun, R et al. (2013). MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer mcf-7 cell line. DNA Cell Biol 32: 699-707.
57. Wu, X, Zhong, D, Gao, Q, Zhai, W, Ding, Z and Wu, J (2013). MicroRNA-34a inhibits human osteosarcoma proliferation by downregulating ether à go-go 1 expression. Int J Med Sci 10: 676-682.
58. Duan, W, Xu, Y, Dong, Y, Cao, L, Tong, J and Zhou, X (2013). Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway. J Radiat Res 54: 611-619.
59. Yang, F, Li, QJ, Gong, ZB, Zhou, L, You, N, Wang, S et al. (2014). MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment. Technol Cancer Res Treat 13: 77-86.
60. Lou, W, Chen, Q, Ma, L, Liu, J, Yang, Z, Shen, J et al. (2013). Oncolytic adenovirus co-expressing miRNA-34a and IL-24 induces superior antitumor activity in experimental tumor model. J Mol Med 91: 715-725.
61. Li, L, Yuan, L, Luo, J, Gao, J, Guo, J and Xie, X (2013). MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med 13: 109-117.
62. Wang, X, Dong, K, Gao, P, Long, M, Lin, F, Weng, Y et al. (2013). microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status. Cancer Biother Radiopharm 28: 45-50.
63. Shen, Z, Zhan, G, Ye, D, Ren, Y, Cheng, L, Wu, Z et al. (2012). MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin. Med Oncol 29: 2473-2480.
64. Cao, W, Yang, W, Fan, R, Li, H, Jiang, J, Geng, M et al. (2014). miR-34a regulates cisplatininduce gastric cancer cell death by modulating PI3K/AKT/survivin pathway. Tumour Biol 35: 1287-1295.
65. Kumar, B, Yadav, A, Lang, J, Teknos, TN and Kumar, P (2012). Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLoS ONE 7: e37601.
66. Kashat, M, Azzouz, L, Sarkar, SH, Kong, D, Li, Y and Sarkar, FH (2012). Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness. Am J Transl Res 4: 432-442.
67. Yang, P, Li, QJ, Feng, Y, Zhang, Y, Markowitz, GJ, Ning, S et al. (2012). TGF-β-miR-34a- CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBVpositive hepatocellular carcinoma. Cancer Cell 22: 291-303.
68. Mandke, P, Wyatt, N, Fraser, J, Bates, B, Berberich, SJ and Markey, MP (2012). MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame. PLoS ONE 7: e42034.
69. Okada, N, Lin, CP, Ribeiro, MC, Biton, A, Lai, G, He, X et al. (2014). A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression. Genes Dev 28: 438-450.
70. Mackiewicz, M, Huppi, K, Pitt, JJ, Dorsey, TH, Ambs, S and Caplen, NJ (2011). Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat 130: 663-679.
71. Mudduluru, G, Ceppi, P, Kumarswamy, R, Scagliotti, GV, Papotti, M and Allgayer, H (2011). Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene 30: 2888-2899.
72. Vo, DT, Qiao, M, Smith, AD, Burns, SC, Brenner, AJ and Penalva, LO (2011). The oncogenic RNA-binding protein Musashi1 is regulated by tumor suppressor miRNAs. RNA Biol 8: 817-828.
73. Muppala, S, Mudduluru, G, Leupold, JH, Buergy, D, Sleeman, JP and Allgayer, H (2013). CD24 induces expression of the oncomir miR-21 via Src, and CD24 and Src are both post-transcriptionally downregulated by the tumor suppressor miR-34a. PLoS ONE 8: e59563.
74. Kim, HR, Roe, JS, Lee, JE, Hwang, IY, Cho, EJ and Youn, HD (2012). A p53-inducible microRNA-34a downregulates Ras signaling by targeting IMPDH. Biochem Biophys Res Commun 418: 682-688.
75. Heinemann, A, Zhao, F, Pechlivanis, S, Eberle, J, Steinle, A, Diederichs, S et al. (2012). Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res 72: 460-471.
76. Yin, D, Ogawa, S, Kawamata, N, Leiter, A, Ham, M, Li, D et al. (2013). miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene 32: 1155-1163.
77. Kaller, M, Liffers, ST, Oeljeklaus, S, Kuhlmann, K, Röh, S, Hoffmann, R et al. (2011). Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol Cell Proteomics 10: M111.010462.
78. Zhao, J, Lammers, P, Torrance, CJ and Bader, AG (2013). TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.). Mol Ther 21: 1678-1686.
79. Garofalo, M, Jeon, YJ, Nuovo, GJ, Middleton, J, Secchiero, P, Joshi, P et al. (2013). MiR-34a/c-Dependent PDGFR-a/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer. PLoS ONE 8: e67581.
80. Jin, K, Xiang, Y, Tang, J, Wu, G, Li, J, Xiao, H et al. (2014). miR-34 is associated with poor prognosis of patients with gallbladder cancer through regulating telomere length in tumor stem cells. Tumour Biol 35: 1503-1510.
81. Davis, BN, Hilyard, AC, Lagna, G and Hata, A (2008). SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454: 56-61.
82. Yamagata, K, Fujiyama, S, Ito, S, Ueda, T, Murata, T, Naitou, M et al. (2009). Maturation of microRNA is hormonally regulated by a nuclear receptor. Mol Cell 36: 340-347.
83. Hau, A, Ceppi, P and Peter, ME (2012). CD95 is part of a let-7/p53/miR-34 regulatory network. PLoS ONE 7: e49636.
84. Rücker, FG, Russ, AC, Cocciardi, S, Kett, H, Schlenk, RF, Botzenhardt, U et al. (2013). Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance. Leukemia 27: 353-361.
85. Ma, Y, Bao-Han, W, Lv, X, Su, Y, Zhao, X, Yin, Y et al. (2013). MicroRNA-34a mediates the autocrine signaling of PAR2-activating proteinase and its role in colonic cancer cell proliferation. PLoS ONE 8: e72383.
86. Craig, VJ, Cogliatti, SB, Imig, J, Renner, C, Neuenschwander, S, Rehrauer, H et al. (2011). Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood 117: 6227-6236.
87. Siemens, H, Jackstadt, R, Hünten, S, Kaller, M, Menssen, A, Götz, U et al. (2011). miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 10: 4256-4271.
88. Rokavec, M, Öner, MG, Li, H, Jackstadt, R, Jiang, L, Lodygin, D et al. (2014). IL-6R/ STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest 124: 1853-1867.
89. Silber, J, Jacobsen, A, Ozawa, T, Harinath, G, Pedraza, A, Sander, C et al. (2012). miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis. PLoS ONE 7: e33844.
90. Zhao, J, Kelnar, K and Bader, AG (2014). In-depth analysis shows synergy between erlotinib and miR-34a. PLoS ONE 9: e89105.
91. Li, XJ, Ji, MH, Zhong, SL, Zha, QB, Xu, JJ, Zhao, JH et al. (2012). MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1. Arch Med Res 43: 514-521.
92. Vinall, RL, Ripoll, AZ, Wang, S, Pan, CX and deVere White, RW (2012). MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer 130: 2526-2538.
93. Akao, Y, Noguchi, S, Iio, A, Kojima, K, Takagi, T and Naoe, T (2011). Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett 300: 197-204.
94. Kojima, K, Fujita, Y, Nozawa, Y, Deguchi, T and Ito, M (2010). MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 70: 1501-1512.
95. Ogawa, T, Saiki, Y, Shiga, K, Chen, N, Fukushige, S, Sunamura, M et al. (2012). miR-34a is downregulated in cis-diamminedichloroplatinum treated sinonasal squamous cell carcinoma patients with poor prognosis. Cancer Sci 103: 1737-1743.
96. Nakatani, F, Ferracin, M, Manara, MC, Ventura, S, Del Monaco, V, Ferrari, S et al. (2012). miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemosensitivity and malignancy. J Pathol 226: 796-805.
97. Kutay, H, Bai, S, Datta, J, Motiwala, T, Pogribny, I, Frankel, W et al. (2006). Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 99: 671-678.
98. Pogribny, IP, Tryndyak, VP, Ross, SA and Beland, FA (2008). Differential expression of microRNAs during hepatocarcinogenesis induced by methyl deficiency in rats. Nutr Rev 66 (suppl. 1): S33-S35.
99. Guo, J, Li, W, Shi, H, Xie, X, Li, L, Tang, H et al. (2013). Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a. Mol Cell Biochem 382: 103-111.
100. Roy, S, Levi, E, Majumdar, AP and Sarkar, FH (2012). Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J Hematol Oncol 5: 58.
101. Kang, J, Kim, E, Kim, W, Seong, KM, Youn, H, Kim, JW et al. (2013). Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines. J Biol Chem 288: 27343-27357.
102. Ji, X, Wang, Z, Geamanu, A, Goja, A, Sarkar, FH and Gupta, SV (2012). Delta-tocotrienol suppresses Notch-1 pathway by upregulating miR-34a in nonsmall cell lung cancer cells. Int J Cancer 131: 2668-2677.
103. Xia, J, Duan, Q, Ahmad, A, Bao, B, Banerjee, S, Shi, Y et al. (2012). Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells. Curr Drug Targets 13: 1750-1756.
104. Tomosugi, M, Sowa, Y, Yasuda, S, Tanaka, R, te Riele, H, Ikawa, H et al. (2012). Retinoblastoma gene-independent G1 phase arrest by flavone, phosphatidylinositol 3-kinase inhibitor, and histone deacetylase inhibitor. Cancer Sci 103: 2139-2143.
105. Chiyomaru, T, Yamamura, S, Fukuhara, S, Yoshino, H, Kinoshita, T, Majid, S et al. (2013). Genistein inhibits prostate cancer cell growth by targeting miR-34a and oncogenic HOTAIR. PLoS ONE 8: e70372.
106. Hui, C, Yujie, F, Lijia, Y, Long, Y, Hongxia, X, Yong, Z et al. (2012). MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis. Breast Cancer Res 14: R80.
107. Chakrabarti, M, Ai, W, Banik, NL and Ray, SK (2013). Overexpression of miR- 7-1 increases efficacy of green tea polyphenols for induction of apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-DZ cells. Neurochem Res 38: 420-432.
108. Chakrabarti, M, Khandkar, M, Banik, NL and Ray, SK (2012). Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells. Brain Res 1454: 1-13.
109. Kota, J, Chivukula, RR, O'Donnell, KA, Wentzel, EA, Montgomery, CL, Hwang, HW et al. (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005-1017.
110. Qiu, X, Friedman, JM and Liang, G (2011). Creating a flexible multiple microRNA expression vector by linking precursor microRNAs. Biochem Biophys Res Commun 411: 276-280.
111. Calimeri, T, Battista, E, Conforti, F, Neri, P, Di Martino, MT, Rossi, M et al. (2011). A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 25: 707-711.
112. Tassone, P, Neri, P, Burger, R, Di Martino, MT, Leone, E, Amodio, N et al. (2012). Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Curr Cancer Drug Targets 12: 814-822.
113. Li, L, Xie, X, Luo, J, Liu, M, Xi, S, Guo, J et al. (2012). Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion. Mol Ther 20: 2326-2334.
114. Kasinski, AL and Slack, FJ (2012). miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res 72: 5576-5587.
115. Iqbal, N, Mei, J, Liu, J and Skapek, SX (2014). miR-34a is essential for p19(Arf)-driven cell cycle arrest. Cell Cycle 13: 792-800.
116. Ahn, YH, Gibbons, DL, Chakravarti, D, Creighton, CJ, Rizvi, ZH, Adams, HP et al. (2012). ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. J Clin Invest 122: 3170-3183.
117. Wiggins, JF, Ruffino, L, Kelnar, K, Omotola, M, Patrawala, L, Brown, D et al. (2010). Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 70: 5923-5930.
118. Trang, P, Wiggins, JF, Daige, CL, Cho, C, Omotola, M, Brown, D et al. (2011). Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 19: 1116-1122.
119. Chen, Y, Zhu, X, Zhang, X, Liu, B and Huang, L (2010). Nanoparticles modified with tumortargeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 18: 1650-1656.
120. Pramanik, D, Campbell, NR, Karikari, C, Chivukula, R, Kent, OA, Mendell, JT et al. (2011). Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 10: 1470-1480.
121. Corney, DC, Hwang, CI, Matoso, A, Vogt, M, Flesken-Nikitin, A, Godwin, AK et al. (2010). Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 16: 1119-1128.
122. Feinberg-Gorenshtein, G, Avigad, S, Jeison, M, Halevy-Berco, G, Mardoukh, J, Luria, D et al. (2009). Reduced levels of miR-34a in neuroblastoma are not caused by mutations in the TP53 binding site. Genes Chromosomes Cancer 48: 539-543.
123. Dijkstra, MK, van Lom, K, Tielemans, D, Elstrodt, F, Langerak, AW, van't Veer, MB et al. (2009). 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Leukemia 23: 625-627.
124. Lodygin, D, Tarasov, V, Epanchintsev, A, Berking, C, Knyazeva, T, Körner, H et al. (2008). Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7: 2591-2600.
125. Siemens, H, Neumann, J, Jackstadt, R, Mansmann, U, Horst, D, Kirchner, T et al. (2013). Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and β-catenin predicts distant metastasis of colon cancer. Clin Cancer Res 19: 710-720.
126. Toyota, M, Suzuki, H, Sasaki, Y, Maruyama, R, Imai, K, Shinomura, Y et al. (2008). Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 68: 4123-4132.
127. Tazawa, H, Tsuchiya, N, Izumiya, M and Nakagama, H (2007). Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA 104: 15472-15477.
128. Pineau, P, Volinia, S, McJunkin, K, Marchio, A, Battiston, C, Terris, B et al. (2010). miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA 107: 264-269.
129. Dang, Y, Luo, D, Rong, M and Chen, G (2013). Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS ONE 8: e61054.
130. Gallardo, E, Navarro, A, Viñolas, N, Marrades, RM, Diaz, T, Gel, B et al. (2009). miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 30: 1903-1909.
131. Franchina, T, Amodeo, V, Bronte, G, Savio, G, Ricciardi, GR, Picciotto, M et al. (2014). Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-ased chemotherapy in advanced non-small cell lung cancer. J Cell Physiol 229: 97-99.
132. Peurala, H, Greco, D, Heikkinen, T, Kaur, S, Bartkova, J, Jamshidi, M et al. (2011). MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer. PLoS ONE 6: e26122.
133. Eichelser, C, Flesch-Janys, D, Chang-Claude, J, Pantel, K and Schwarzenbach, H (2013). Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin Chem 59: 1489-1496.
134. Javeri, A, Ghaffarpour, M, Taha, MF and Houshmand, M (2013). Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis. Med Oncol 30: 413.
135. Nugent, M, Miller, N and Kerin, MJ (2012). Circulating miR-34a levels are reduced in colorectal cancer. J Surg Oncol 106: 947-952.
136. Tabernero, J, Shapiro, GI, LoRusso, PM, Cervantes, A, Schwartz, GK, Weiss, GJ et al. (2013). First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3: 406-417.
137. Lee, JM, Yoon, TJ and Cho, YS (2013). Recent developments in nanoparticle-based siRNA delivery for cancer therapy. Biomed Res Int 2013: 782041.
138. Maeda, H, Wu, J, Sawa, T, Matsumura, Y and Hori, K (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65: 271-284.
139. Basile, L, Pignatello, R and Passirani, C (2012). Active targeting strategies for anticancer drug nanocarriers. Curr Drug Deliv 9: 255-268.
140. De Rosa, G, De Stefano, D and Galeone, A (2010). Oligonucleotide delivery in cancer therapy. Expert Opin Drug Deliv 7: 1263-1278.
141. Lv, H, Zhang, S, Wang, B, Cui, S and Yan, J (2006). Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 114: 100-109.
142. Scognamiglio, I, Di Martino, MT, Campani, V, Virgilio, A, Galeone, A, Gullà, A et al. (2014). Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma. Biomed Res Int 2014: 217365.
143. Deng, X, Cao, M, Zhang, J, Hu, K, Yin, Z, Zhou, Z et al. (2014). Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials 35: 4333-4344.
144. Wang, S, Cao, M, Deng, X, Xiao, X, Yin, Z, Hu, Q, Zhou, Z, Zhang, F, Zhang, R, Wu, Y, Sheng, W, Zeng, Y. (2014) Degradable Hyaluronic Acid/Protamine Sulfate Interpolyelectrolyte Complexes as miRNA-Delivery Nanocapsules for Triple-Negative Breast Cancer Therapy. Adv Healthc Mater. 9.
145. Tivnan, A, Orr, WS, Gubala, V, Nooney, R, Williams, DE, McDonagh, C, Prenter, S, Harvey, H, Domingo-Fernández, R, Bray, IM, Piskareva, O, Ng, CY, Lode, HN, Davidoff, AM, Stallings, RL. (2012) Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One; 7:e38129.
146. Hu, QL, Jiang, QY, Jin, X, Shen, J, Wang, K, Li, YB, Xu, FJ, Tang, GP, Li, ZH. (2013) Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model. Biomaterials; 34:2265-76.
147. Dicitore, A, Caraglia, M, Gaudenzi, G, Manfredi, G, Amato, B, Mari, D et al. (2014). Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-? (PPAR-?): at the cross-road of pancreatic cancer cell proliferation. Biochim Biophys Acta 1845: 42-52.
148. Vitale, G, Zappavigna, S, Marra, M, Dicitore, A, Meschini, S, Condello, M et al. (2012). The PPAR-? agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells. Biotechnol Adv 30: 169-184.
149. Vitale, G, van Eijck, CH, van Koetsveld Ing, PM, Erdmann, JI, Speel, EJ, van der Wansem Ing, K et al. (2007). Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann Surg 246: 259-268.